Official websites use .gov
A
.gov
website belongs to an official government organization in the
United States.
Secure .gov websites use HTTPS
A
lock
(
) or
https://
means you’ve safely connected to the .gov website. Share sensitive
information only on official, secure websites.
Study Design: Interventional
Conditions: Diabetes Mellitus, Diabetes Mellitus, Type 1
Division: DEM
Treatment: Islet Cell Transplantation
Available Genotype Data: No
Image Summary: No
Transplant Type: None
Does it have dialysis patients: No
Clinical Trials URL:
https://clinicaltrials.gov/ct2/show/NCT00789308
Study Website: https://www.citisletstudy.org/studies.html
Data Package Version Number: 1 (May 13, 2019)
DOI: 10.58020/v6zz-1r31
How to cite this dataset: Clarke, William (2024). Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation (V1) [Dataset]. NIDDK Central Repository. https://doi.org/10.58020/v6zz-1r31
Data availability statement: Data from the Safety and Effectiveness of Low Molecular Weight Sulfated Dextran in Islet Transplantation [(V1)/https://doi.org/10.58020/v6zz-1r31] reported here are available for request at the NIDDK Central Repository (NIDDK-CR) website, Resources for Research (R4R), https://repository.niddk.nih.gov/.
The CIT consortium conducted a total of 9 studies across North America (CIT02 through CIT08) and the Nordic region (CIT01). CIT08 was a long-term follow-up study for interested participants at the North American sites. The target population is individuals with type 1 diabetes, normal kidney function, and intractable hypoglycemia. All studies treated participants with up to 3 separate infusions of islets. CIT01 participants were randomized to study treatment including Low Molecular Weight Sulfated Dextran (LMW-DS) and study treatment without LMW-DS. Subjects in both arms received induction and maintenance immunosuppression consisting of ATG (basiliximab instead of ATG for the 2nd and 3rd transplants, if applicable), etanercept, sirolimus, and tacrolimus. CIT01 subjects randomized to the LMW-DS arm also received LMW-DS before and during islet transplant.
The primary objective is to evaluate the safety and efficacy of Low Molecular Weight Dextran Sulfate (LMW-DS) to enhance engraftment and prevent IBMIR in islet transplantation to Type 1 diabetic subjects. The secondary objective is to gather additional safety and efficacy information about the combination of Low Molecular Weight Sulfated Dextran with islet transplantation.
The level of stimulated c-peptide at 90-minutes derived from the mixed-meal tolerance test (MMTT) at 75+/-5 days following the first islet infusion.
This study has ended.
Study Datasets Only
| Codebooks |
 |
Data_Dictionary (PDF) - 978.3 KB | |
| |
DSIC (PDF) - 334.2 KB | |
| |
Forms (PDF) - 925.2 KB | |
| |
Manual_of_Procedures (PDF) - 1.7 MB | |
| |
Protocol (PDF) - 584.3 KB | |
| |
Roadmap (PDF) - 190.9 KB |
If you need accessible versions of documents, please email your request to NIDDK-CRsupport@niddk.nih.gov.
